IDEXX Laboratories, Inc. Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $4.6B+16.8% YoYTTM through 30 Jun 2026
Net Income $1.1B+28.4% YoYTTM through 30 Jun 2026
Free Cash Flow $1.3BTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 59.8% |
| EBITDA Margin | 35.4% |
| Operating Margin | 32.7% |
| Net Margin | 25.0% |
Returns
66.2%ROE
33.1%ROA
61.1%ROIC
Balance Sheet Health
Debt / Equity0.28x
Current Ratio1.11x
Net Debt$909.5M
Cash & Equivalents$196.9M
Quality Metrics
Altman Z-Score19.12
Piotroski F-Score9 / 9
FCF Margin27.5%
Rule of 4031.3
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $4.3B
Diluted EPS$14.23TTMFY2025: $13.08
Dividend
No dividend
Capital Allocation
R&D Spend$261.5M
Capex Intensity2.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Companion Animal Group | +15.0% | View detailsFor the full year 2026, IDEXX raised its outlook for CAG Diagnostics recurring revenue reported growth to 9.6% - 11.6% and organic growth to 8.7% - 10.7%, reflecting stronger expected performance in CAG Diagnostics recurring revenue. | |
| Water | |||
| Livestock and Poultry Diagnostics |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.